The effect of methylphenidate intake on brain structure in adults with ADHD in a placebo-controlled randomized trial.
J Psychiatry Neurosci
; 41(6): 422-430, 2016 10.
Article
em En
| MEDLINE
| ID: mdl-27575717
ABSTRACT
BACKGROUND:
Based on animal research several authors have warned that the application of methylphenidate, the first-line drug for the treatment of attention-deficit/hyperactivity disorder (ADHD), might have neurotoxic effects potentially harming the brain. We investigated whether methylphenidate application, over a 1-year period, results in cerebral volume decrease.METHODS:
We acquired structural MRIs in a double-blind study comparing methylphenidate to placebo. Global and regional brain volumes were analyzed at baseline, after 3 months and after 12 months using diffeomorphic anatomic registration through exponentiated lie algebra.RESULTS:
We included 131 adult patients with ADHD into the baseline sample, 98 into the 3-month sample (54 in the methylphenidate cohort and 44 in the placebo cohort) and 76 into the 1-year sample (37 in the methylphenidate cohort and 29 in the placebo cohort). Methylphenidate intake compared with placebo did not lead to any detectable cerebral volume loss; there was a trend toward bilateral cerebellar grey matter increase.LIMITATIONS:
Detecting possible neurotoxic effects of methylphenidate might require a longer observation period.CONCLUSION:
There is no evidence of grey matter volume loss after 1 year of methylphenidate treatment in adult patients with ADHD.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Transtorno do Deficit de Atenção com Hiperatividade
/
Encéfalo
/
Estimulantes do Sistema Nervoso Central
/
Metilfenidato
Tipo de estudo:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
Limite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
J Psychiatry Neurosci
Ano de publicação:
2016
Tipo de documento:
Article